Capacity Ramp & Premiumization Test — Allied Blenders Q2 In Focus
New Moradabad facility online, premium launches in flight, but margin pressure from capex. Street expects steady growth within guidance; watch utilization and mix traction on October 27.
Allied Blenders enters Q2 FY2027 at an inflection: Moradabad bottling facility went live on October 19, marking the first major capacity addition. The street's focus will be on three threads: (1) what revenue growth looks like as the facility ramps, (2) whether premiumization traction from recent product launches (The Indian Edit whisky, Officer's Choice Blue repackaging, Malaysia export push) translates to stronger gross margins, and (3) whether near-term capex (₹293–500 Cr for Moradabad expansion, ₹115 Cr malt distillery) pressures EBITDA despite strong topline momentum.
What to Expect
~₹10.5–11 Cr
On-plan growth ~10–11% vs Q1 FY27 (₹9.79 Cr, +6.08% YoY); annual guidance 11.9% tracks here
Watch for compression
Moradabad ramp-up and depreciation will test margins; premium mix offset is the upside case
Incremental mix
New launches + Malaysia local production + Officer's Choice premiumization — gross margin story hinges on this
A strong Q2 would show revenue within guidance, flat-to-modest margin decline (1–2 bps) as the Moradabad facility utilization ramps, and evidence of premiumization (higher ASP, better product mix). A weak Q2 would mean revenue below ₹10 Cr YoY growth, margin compression >200 bps, or signs of execution delays at the new facility. The street currently prices ABDL at ₹739.95 (Oct 19), above the June 2026 analyst consensus target of ₹699–708, implying execution expectations are high.
On Track?
ABDL is tracking its stated full-year guidance (11.9% revenue CAGR FY26–28E, 26.1% earnings growth). Q1 delivered 6.08% YoY growth; Q2 needs ~10%+ growth to stay in the band. The Moradabad facility commissioning mid-quarter (Oct 19) means limited revenue contribution this quarter—impact accelerates Q3 onwards. NCLT merger order (received late Aug) clears one M&A overhang; insider promoter stake sales (1.97% by Bina Kishore Chhabria in Sept) are routine liquidity reshuffles, not distress.
Street View
Since Last Quarter
Oct 19
Moradabad bottling facility commissioned
6M cases/annum capacity live; ramp TBD
Oct 15
Board approval for Oct 27 result announcement
Standard intimation
Oct 15
ABD Maestro subsidiary wins 'Company of the Year 2026'
Brand strength signal
Oct 1
CSD arbitration terminated (Arbitrator ruling Sept 26)
Legal overhang cleared
Sep 25–24
Promoter Bina Kishore Chhabria sells 1.97% stake (55L shares)
Open market sale; MPS compliance
Sep 15
Malt spirits license granted by Telangana
Regulatory approval for new facility
Sep 11
₹115 Cr investment approved for new malt distillery
Long-term capacity play
Sep 11
Premium whisky 'The Indian Edit' launched
Premiumization leg
Aug 24
Officer's Choice Blue local production begins in Malaysia
Export/JV revenue stream
Aug 6
₹293–500 Cr capex approved for Moradabad expansion
Multi-phase growth capex
What to Watch on Result Day
1 · Moradabad utilization & revenue mix
Facility went live Oct 19. Q2 will show minimal contribution (likely <5% of quarterly revenue). Listen for management commentary on: expected ramp curve, capacity utilization trajectory, and what product mix (domestic spirits, malt, exports) will drive the facility. This sets tone for H2 and FY28 growth acceleration.
2 · Premiumization traction & ASP uplift
Indian Edit and Officer's Choice Blue repack launched Sept–Aug. Q2 revenue will include partial run-rates. Management should clarify: incremental volume/ASP contribution, consumer adoption velocity, and margin accretion. If mix is accelerating, gross margin can offset capex depreciation headwind.
3 · EBITDA margin & capex outlook
Capex guidance is aggressive (₹300–500 Cr over FY27–28). Q2 EBITDA margin will likely show modest compression (1–3%) vs prior year due to depreciation. Confirm: full-year capex guidance, expected ROIC timeline for Moradabad, and any impact on dividend payout. Street sensitivity is high—margins matter as much as revenue.
ABDL is at an inflection between capacity growth and premiumization execution. The stock at ₹740 embeds expectations of steady guidance delivery and successful Moradabad ramp. Q2 will be a transition quarter—limited facility contribution but strong signals needed on product traction and capex absorption. Management's commentary on utilization curves, ASP uplift, and near-term margin trajectory will drive post-result re-rating. Watch for execution confidence; Street buy ratings assume ABDL delivers FY28 growth acceleration off the new capex foundation.